Scientists identified and characterized resistance mechanisms to a FIRINOX chemotherapy regimen because it is the most aggressive regimen currently used clinically for patients with pancreatic ductal adenocarcinoma.
[Science Translational Medicine]
Sorry, but the selected Zotpress account can't be found.